| Pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 19485926 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The last 10 years have seen significant advances in the understanding of the pathophysiology and treatment of pulmonary arterial hypertension (PAH). This has included new insights into the genetics, cell-signalling pathways and pathological changes seen in the small pulmonary arteries as well as the introduction of new treatments which have improved prognosis. The classification of pulmonary hypertension (PH) has also been changed several times, most recently in 2003. It now divides forms of PH into 5 broad groups according to their pathophysiology and response to treatment. This review focuses primarily on the advances that have been made in the comprehension and treatment of Group 1 (PAH); however reference is also made to other groups within the classification. Pharmacologic treatment now includes calcium-channel blockers, endothelin antagonists, prostanoids, phosphodiesterase type 5 inhibitors, anticoagulants and diuretics. There are 2 recent sets of guidelines directing treatment, one published by the American College of Chest Physicians in 2007 and the most recent published by the National Pulmonary Hypertension Centres of the UK and Ireland in 2008. The recent advances in understanding of the underlying cellular mechanisms have also opened the doorway to new potential therapies such as stem cell transplantation and the targeting of platelet-derived factors and apoptosis. |
| | |
Authors:
|
Christiana Burt; Joanna Pepke-Zaba; Florian Falter |
Related Documents
:
|
17338926 - Pathology of pulmonary hypertension. 20525186 - Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report. 20427556 - Idiopathic pulmonary arterial hypertension. 23505276 - Recurrent facial hemiparesis due to dolichoectatic vertebrobasilar artery: an unusual a... 1892666 - Anomalous origin of the left coronary artery from the pulmonary artery: repair by aorti... 21167726 - Radial artery versus saphenous vein conduits for coronary artery bypass surgery: forty ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current vascular pharmacology Volume: 8 ISSN: 1875-6212 ISO Abbreviation: Curr Vasc Pharmacol Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-05 Completed Date: 2011-01-13 Revised Date: 2012-03-26 |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 412-20 Citation Subset: IM |
Affiliation:
|
Department of Anaesthesia and Intensive Care, Papworth Hospital, Cambridge, CB23 3RE, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / therapeutic use Calcium Channel Blockers / therapeutic use Cell Proliferation Diuretics / therapeutic use Humans Hypertension, Pulmonary / diagnosis*, physiopathology, therapy* Phosphodiesterase Inhibitors / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Diuretics; 0/Phosphodiesterase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Why are People with "Poor Lung Function" at Increased Atherothrombotic Risk?: A Critical Review with...
Next Document: Genetic and Molecular Determinants of Atherosclerotic Plaque Instability.